Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers - Full Text View

Purpose

Study to assess the ability of healthy subjects to build anitbodies to tetanus and pneumococcal vaccines after receiving a single intravenous dose of Abatacept, a drug which is being developed for the treatment of Rheumatoid Arthritis and which can affect the immune system.

Condition	Intervention	Phase
Rheumatoid Arthritis	Drug: Tetanus + pnemococcal vaccines alone Drug: Abatacept + vaccines Drug: Abatacept + Vaccines	Phase I

MedlinePlus related topics:

Rheumatoid Arthritis Tetanus

Drug Information available for:

Tetanus Vaccine Abatacept

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Pharmacodynamics Study

Official Title:	An Exploratory Study to Evaluate the Effect of Abatacept (BMS-188667) on the Antibody Response Following Tetanus Toxoid and 23-Valent Pneumococcal Vaccinations in Healthy Subjects

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:

Assess effect of single 750mg dose of Abatacept on antibody response to tetanus toxioid and 23-valent pneumococcal vaccines.

Secondary Outcome Measures:

Assess safety and tolerability of Abatacept given in conjunction with tetanus toxoid and 23-valent pneumococcal vaccines.

Estimated Enrollment:	80
Study Start Date:	August 2004

Arms	Assigned Interventions
Group 1: Experimental	Drug: Tetanus + pnemococcal vaccines alone 0 mg + vaccines, Single dose, 28 days.
Group 2: Active Comparator	Drug: Abatacept + vaccines Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 70 days.
Group 3: Active Comparator	Drug: Abatacept + vaccines Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 56 days.
Group 4: Active Comparator	Drug: Abatacept + Vaccines parenteral, IV, 750 mg abatacept + vaccines, Single dose, 84 days.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Healthy Subjects
Body Weight between 60 and 100 kg.
Males and Females must be using adequate contraceptive methods during study and for 10 weeks after dose of study mediciation.

Exclusion Criteria:

Females who are prgnant or breastfeeding
History of autoimmune disorder, immunodeficiency, or infection within past 3 months.
Active TB requiring treatment within the previous 3 years.
Positive breast cancer screen, PPD test.
Vaccination with tetanus or pneumococcal vaccine within 5 years.
Vaccination with any live vaccine within 4 weeks.
History of drug or alcohol abuse.
Any significant allergy.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00279734

Locations


United States, Kansas
	Qutintiles Phase I Services
	Lenexa, Kansas, United States

United States, Maryland
	Parexel International Corp
	Baltimore, Maryland, United States

United States, Texas
	PPD Development
	Austin, Texas, United States

Sponsors and Collaborators

Bristol-Myers Squibb

Investigators


Study Director:	Bristol-Myers Squibb	Bristol-Myers Squibb

More Information

BMS Clinical Trials Disclosure This link exits the ClinicalTrials.gov site

For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm This link exits the ClinicalTrials.gov site

Publications indexed to this study:

Tay L, Leon F, Vratsanos G, Raymond R, Corbo M. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther. 2007;9(2):R38.

Study ID Numbers:	IM101-049
First Received:	January 19, 2006
Last Updated:	August 13, 2008
ClinicalTrials.gov Identifier:	NCT00279734
Health Authority:	United States: Food and Drug Administration

Keywords provided by Bristol-Myers Squibb:

Rheumatoid Arthritis

Study placed in the following topic categories:

Antibodies

Abatacept

Autoimmune Diseases

Musculoskeletal Diseases

Joint Diseases

Arthritis

Connective Tissue Diseases

Arthritis, Rheumatoid

Healthy

Rheumatic Diseases

Tetanus

Additional relevant MeSH terms:

Immunologic Factors

Immune System Diseases

Therapeutic Uses

Physiological Effects of Drugs

Antirheumatic Agents

Immunosuppressive Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on October 24, 2008

Sponsored by:	Bristol-Myers Squibb
Information provided by:	Bristol-Myers Squibb
ClinicalTrials.gov Identifier:	NCT00279734